Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N-myristoyltransferase 2 (NMT2) is an enzyme that catalyzes the covalent attachment of myristic acid to the N-terminal glycine residue of substrate proteins. This modification, known as N-terminal myristoylation, is crucial for regulating protein function and localization. NMT2 plays roles in cell growth, apoptosis regulation, cardiac remodeling, and potentially tumor suppression. It has emerged as a potential therapeutic target for cancer and cardiac diseases, with inhibitors under investigation for their ability to disrupt aberrant signaling pathways dependent on protein lipidation modifications like myristoylation.
Inhibition of N-myristoylation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycylpeptide-N-tetradecanoyltransferase 2.